Compare RGP & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGP | RANI |
|---|---|---|
| Founded | 1996 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.4M | 106.9M |
| IPO Year | 2000 | 2021 |
| Metric | RGP | RANI |
|---|---|---|
| Price | $2.80 | $0.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $5.67 | ★ $7.20 |
| AVG Volume (30 Days) | 406.2K | ★ 503.4K |
| Earning Date | 10-07-2026 | 11-05-2026 |
| Dividend Yield | ★ 9.37% | N/A |
| EPS Growth | ★ 79.14 | 57.14 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $452,006,000.00 | $1,633,000.00 |
| Revenue This Year | N/A | $283.19 |
| Revenue Next Year | $7.01 | $5.99 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 58.85 |
| 52 Week Low | $2.88 | $0.45 |
| 52 Week High | $5.37 | $3.87 |
| Indicator | RGP | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 19.83 | 48.95 |
| Support Level | N/A | $0.73 |
| Resistance Level | $4.63 | $0.85 |
| Average True Range (ATR) | 0.18 | 0.05 |
| MACD | -0.09 | 0.00 |
| Stochastic Oscillator | 0.41 | 57.97 |
Resources Connection Inc is a professional services firm. Its segments include On-Demand Talent provides businesses with a go-to source for bringing in experts when its needed, serving the office of the CFO; Consulting drives transformation across people, processes and technology across domain areas including finance, technology and digital, risk and compliance and operational performance; Europe & Asia Pacific offers both on-demand and consulting services to clients throughout Europe and Asia Pacific; Outsourced Services; and Sitrick. It derives the majority of revenue from On-Demand Talent segment. Geographically, it operates in United States and internationally.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.